Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 26.23% is 23% below its 5-year average of 34.26%, around the middle of its 5-year range (6.69%–35.94%).
5.38% below its 12-month average of 27.72%.
Reported quarterly gross margin; no daily interpolation.
GROSS MARGIN
26.23%
GROSS MARGIN AVG TTM
27.72%
GROSS MARGIN AVG 3Y
34.19%
GROSS MARGIN AVG 5Y
34.26%
GROSS MARGIN AVG 10Y
34.58%
GROSS MARGIN AVG 15Y
31.30%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-5.38%
CURRENT VS 3Y AVG
-23.28%
CURRENT VS 5Y AVG
-23.45%
CURRENT VS 10Y AVG
-24.14%
CURRENT VS 15Y AVG
-16.21%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
58.99%
median of 90 covered companies
CURRENT VS SECTOR MEDIAN
-55.54%
vs the sector median at left
IQVIA Holdings Inc.
Market Cap
$42.08B
Gross Margin
26.23%
TTM Avg
27.72%
3Y Avg
34.19%
5Y Avg
34.26%
Market Cap
$42.87B
Gross Margin
52.47%
TTM Avg
50.27%
3Y Avg
48.88%
5Y Avg
48.29%
Market Cap
$41.12B
Gross Margin
62.45%
TTM Avg
61.42%
3Y Avg
60.55%
5Y Avg
59.83%
Market Cap
$40.84B
Gross Margin
53.73%
TTM Avg
53.36%
3Y Avg
52.95%
5Y Avg
53.14%
Market Cap
$49.64B
Gross Margin
46.12%
TTM Avg
45.33%
3Y Avg
44.44%
5Y Avg
44.19%
Market Cap
$49.89B
Gross Margin
77.98%
TTM Avg
78.79%
3Y Avg
78.80%
5Y Avg
77.78%
Market Cap
$34.17B
Gross Margin
79.72%
TTM Avg
83.69%
3Y Avg
83.53%
5Y Avg
83.62%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IQVIA Holdings Inc. (IQV) | $42.08B | 26.23% | 27.72% | 34.19% | 34.26% |
| Teva Pharmaceutical Industries Limited (TEVA)vs › | $42.87B | 52.47% | 50.27% | 48.88% | 48.29% |
| IDEXX Laboratories, Inc. (IDXX)vs › | $41.12B | 62.45% | 61.42% | 60.55% | 59.83% |
| Agilent Technologies, Inc. (A)vs › | $40.84B | 53.73% | 53.36% | 52.95% | 53.14% |
| Humana Inc. (HUM)vs › | $47.87B | 13.65% | 14.54% | 16.14% | 17.03% |
| Becton, Dickinson and Company (BDX)vs › | $49.64B | 46.12% | 45.33% | 44.44% | 44.19% |
| Edwards Lifesciences Corporation (EW)vs › | $49.89B | 77.98% | 78.79% | 78.80% | 77.78% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $34.17B | 79.72% | 83.69% | 83.53% | 83.62% |
| Alcon Inc. (ALC)vs › | $33.65B | 56.45% | 55.42% | 55.20% | 53.33% |
| DexCom, Inc. (DXCM)vs › | $32.08B | 62.47% | 60.28% | 62.12% | 63.92% |
Gross Margin
26.2%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 32.85% |
| 2026-03-31 | 32.64% |
| 2025-12-31 | 6.69% |
| 2025-09-30 | 33.49% |
| 2025-06-30 | 32.94% |
| 2025-03-31 | 33.90% |
| 2024-12-31 | 34.82% |
| 2024-09-30 | 35.37% |
| 2024-06-30 | 27.71% |
| 2024-03-31 | 34.60% |
| 2023-12-31 | 35.94% |
| 2023-09-30 | 35.06% |
| 2023-06-30 | 34.47% |
| 2023-03-31 | 34.34% |
| 2022-12-31 | 35.62% |
| 2022-09-30 | 34.84% |
| 2022-06-30 | 26.77% |
| 2022-03-31 | 34.89% |
| 2021-12-31 | 34.98% |
| 2021-09-30 | 33.56% |
| 2021-06-30 | 32.45% |
| 2021-03-31 | 32.74% |
| 2020-12-31 | 34.14% |
| 2020-09-30 | 35.39% |
| 2020-06-30 | 20.29% |
| 2020-03-31 | 33.77% |
| 2019-12-31 | 34.34% |
| 2019-09-30 | 22.37% |
| 2019-06-30 | 34.34% |
| 2019-03-31 | 34.87% |
| 2018-12-31 | 35.19% |
| 2018-09-30 | 35.31% |
| 2018-06-30 | 34.79% |
| 2018-03-31 | 35.54% |
| 2017-12-31 | 37.64% |
| 2017-09-30 | 34.67% |
| 2017-06-30 | 33.89% |
| 2017-03-31 | 35.34% |
| 2016-12-31 | 36.85% |
| 2016-09-30 | 29.46% |
| 2016-06-30 | 27.82% |
| 2016-03-31 | 27.79% |
| 2015-12-31 | 28.37% |
| 2015-09-30 | 28.81% |
| 2015-06-30 | 27.05% |
| 2015-03-31 | 27.32% |
| 2014-12-31 | 27.58% |
| 2014-09-30 | 26.43% |
| 2014-06-30 | 26.92% |
| 2014-03-31 | 27.65% |
| 2013-12-31 | 26.25% |
| 2013-09-30 | 27.77% |
| 2013-06-30 | 25.20% |
| 2013-03-31 | 25.74% |
| 2012-12-31 | 24.82% |
| 2012-09-30 | 25.13% |
| 2012-06-30 | 25.73% |
| 2012-03-31 | 25.72% |
